Myriad International Gmbh

Other

Sividon Diagnostics Gmbh

Biontech Diagnostics Gmbh

Wirtz, Ralph

Ralf Kronenwett

Guido Hennig

Udo Stropp

Mathias Gehrmann

Christian Von Törne

Christoph Petry

Inke Sabine Feder

Karsten Weber

Mareike Dartmann

Ralph Markus Wirtz

Jan Brase

Karin Fisch

Marcus Schmidt

Guido Henning

George Fountzilas

Jan Christoph Brase

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Method for breast cancer recurrence prediction under endocrine treatment

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:

Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes S100P and PCSK6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen.

Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer

The present invention is related to a method for analyzing a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of three genes of interest, said genes being correlated with the Estrogen receptor (ESR) status in the sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c); and treating based on said outcome.

Method for predicting therapy responsiveness in basal like tumors

Growing community of inventors

Cologne, Germany

Ralf Kronenwett